Galectin Therapeutics (GALT) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18).
For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Mosaic sets pricing for tender offers on up to $1.4B in debt
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
